Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 8/20 | 0.49 |
| ▸ | DDB1 | Q16531 | 5/20 | 0.49 |
| ▸ | IKZF1 | Q13422 | 5/20 | 0.42 |
| ▸ | IKZF2 | Q9UKS7 | 7/20 | 0.40 |
| ▸ | IKZF3 | Q9UKT9 | 4/20 | 0.39 |
| ▸ | TNF | P01375 | 3/20 | 0.37 |
| ▸ | IL1B | P01584 | 3/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28588984 | 0.94 | CRBN (0.55) | CRBNDDB1IKZF1IKZF2IKZF3 | |
| SCHEMBL23915922 | 0.94 | CRBN (0.55) | CRBNDDB1IKZF1IKZF2IKZF3 | |
| SCHEMBL28584135 | 0.83 | CRBN (0.65) | CRBNDDB1IKZF1IKZF2IKZF3 | |
| SCHEMBL23915841 | 0.83 | CRBN (0.65) | CRBNDDB1IKZF1IKZF2IKZF3 | |
| SCHEMBL24269118 | 0.79 | CRBN (0.61) | CRBNDDB1IKZF1IKZF2IKZF3 | |
| SCHEMBL23806442 | 0.79 | CRBN (0.61) | CRBNDDB1IKZF1IKZF2IKZF3 | |
| SCHEMBL22511566 | 0.79 | CRBN (0.61) | CRBNDDB1IKZF1IKZF2IKZF3 | |
| SCHEMBL24132316 | 0.79 | CRBN (0.58) | CRBNDDB1IKZF1IKZF2IKZF3 | |
| SCHEMBL23945328 | 0.77 | CRBN (0.58) | CRBNDDB1IKZF1IKZF2IKZF3 | |
| SCHEMBL24269120 | 0.74 | CRBN (0.65) | CRBNDDB1IKZF1IKZF3TNF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4736882-A2 | TROPOMYOSIN RECEPTOR KINASE (TRK) DEGRADATION COMPOUNDS AND METHODS OF USE | Cullgen (Shanghai), Inc. (CN) | 2026-05-06 | — | — | EP | disclosed |
| EP-3841098-B1 | TROPOMYOSIN RECEPTOR KINASE (TRK) DEGRADATION COMPOUNDS AND METHODS OF USE | CULLGEN SHANGHAI INC (CN) | 2026-01-14 | — | — | EP | disclosed |
| US-20250388587-A1 | TROPOMYOSIN RECEPTOR KINASE (TRK) DEGRADATION COMPOUNDS AND METHODS OF USE | CULLGEN SHANGHAI INC (CN) | 2025-12-25 | — | — | US | disclosed |
| US-12410171-B2 | Tropomyosin receptor kinase (TRK) degradation compounds and methods of use | CULLGEN (SHANGHAI), INC. (CN) | 2025-09-09 | — | — | US | disclosed |
| US-20240400570-A1 | TROPOMYOSIN RECEPTOR KINASE (TRK) DEGRADATION COMPOUNDS AND METHODS OF USE | CULLGEN (SHANGHAI), INC. (CN) | 2024-12-05 | — | — | US | disclosed |
| US-12065442-B2 | Tropomyosin receptor kinase (TRK) degradation compounds and methods of use | CULLGEN (SHANGHAI), INC. (CN) | 2024-08-20 | — | — | US | disclosed |
| US-20230257380-A1 | TROPOMYOSIN RECEPTOR KINASE (TRK) DEGRADATION COMPOUNDS AND METHODS OF USE | CULLGEN (SHANGHAI), INC. (CN) | 2023-08-17 | — | — | US | disclosed |
| EP-4110772-A1 | TROPOMYOSIN RECEPTOR KINASE (TRK) DEGRADATION COMPOUNDS AND METHODS OF USE | Cullgen (Shanghai), Inc. (CN) | 2023-01-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230257380-A1 | TROPOMYOSIN RECEPTOR KINASE (TRK) DEGRADATION COMPOUNDS AND METHODS OF USE | MUSK, ERBB2, NTRK1 | CRBN 330/4885DDB1 480/4885IKZF1 1930/4885 |
| US-12410171-B2 | Tropomyosin receptor kinase (TRK) degradation compounds and methods of use | MUSK, ERBB2, NTRK1 | CRBN 330/4885DDB1 480/4885IKZF1 1930/4885 |
| US-20250388587-A1 | TROPOMYOSIN RECEPTOR KINASE (TRK) DEGRADATION COMPOUNDS AND METHODS OF USE | ERBB2, MUSK, ERBB3 | CRBN 149/4885DDB1 1222/4885IKZF1 2277/4885 |
| US-20240400570-A1 | TROPOMYOSIN RECEPTOR KINASE (TRK) DEGRADATION COMPOUNDS AND METHODS OF USE | MUSK, ERBB2, NTRK1 | CRBN 330/4885DDB1 480/4885IKZF1 1930/4885 |
| US-12065442-B2 | Tropomyosin receptor kinase (TRK) degradation compounds and methods of use | MUSK, NTRK1, ERBB2 | CRBN 194/4885DDB1 418/4885IKZF1 1556/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.